(Total Views: 444)
Posted On: 02/23/2019 7:52:07 AM
Post# of 36566
Barnard gets the $2 by comparing NGIO to a company Merck just acquired. But then he immediately says that may be on the low end, and says this other company was under stress, laid off 20% of its people, and has discontinued one line of IP development.
So we may be comparing apples to oranges here. Barnard just a month ago compared Generex/NGIO to two companies that were bought for one billion and 12 billion. It looks like he just doesn't really know and is throwing out wild guesses.
NGIO will IPO on a major exchange, so that price will not be $2, one would think. Plus, they are adding more IP, which we will learn about Tues. I would think the IPO price will not be under $5.
So we may be comparing apples to oranges here. Barnard just a month ago compared Generex/NGIO to two companies that were bought for one billion and 12 billion. It looks like he just doesn't really know and is throwing out wild guesses.
NGIO will IPO on a major exchange, so that price will not be $2, one would think. Plus, they are adding more IP, which we will learn about Tues. I would think the IPO price will not be under $5.

